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The continuous delivery of glucose to the brain is
critically important to the maintenance of normal met-
abolic function. However, elucidation of the hormonal
regulation of in vivo cerebral glucose metabolism in
humans has been limited by the lack of direct, noninva-
sive methods with which to measure brain glucose. In
this study, we sought to directly examine the effect of
insulin on glucose concentrations and rates of glucose
transport/metabolism in human brain using 1H-magnetic
resonance spectroscopy at 4 Tesla. Seven subjects par-
ticipated in paired hyperglycemic (16.3  0.3 mmol/l)
clamp studies performed with and without insulin. Brain
glucose remained constant throughout (5.3 0.3 mol/g
wet wt when serum insulin  16  7 pmol/l vs. 5.5  0.3
mol/g wet wt when serum insulin  668  81 pmol/l,
P  NS). Glucose concentrations in gray matter–rich
occipital cortex and white matter–rich periventricular
tissue were then simultaneously measured in clamps,
where plasma glucose ranged from 4.4 to 24.5 mmol/l
and insulin was infused at 0.5 mU  kg–1  min–1. The
relationship between plasma and brain glucose was linear
in both regions. Reversible Michaelis-Menten kinetics
fit these data best, and no differences were found in the
kinetic constants calculated for each region. These data
support the hypothesis that the majority of cerebral
glucose uptake/metabolism is an insulin-independent
process in humans. Diabetes 50:2203–2209, 2001
The brain relies on the continuous delivery ofglucose via the blood to maintain normal meta-bolic function. How glucose delivery into thecentral nervous system is regulated and how that
delivery is altered by different metabolic conditions in the
living human have been difficult to ascertain. In particular,
the role of insulin in the regulation of cerebral glucose
metabolism has been difficult to directly assess. Although
evidence acquired using both in vitro and in vivo ap-
proaches support and refute the hypothesis that insulin
regulates the entry of glucose into brain tissue (1–9),
studies performed in living animals have been limited by
their inability to directly measure cerebral glucose con-
centrations.
The brain is composed of both gray and white matter.
Both rely on glucose for the maintenance of normal
function, but the rates at which they metabolize glucose
have been found to be different (9,10). Whether these
differences in glucose metabolism equate to differences
in cerebral glucose concentrations and whether insulin
differentially regulates regional cerebral glucose metabo-
lism have not been directly examined in humans because,
until recently, direct methods to measure brain glucose
concentrations in healthy subjects have not been feasible.
Invasive methods to measure intracerebral glucose con-
centrations, such as the use of an implanted equilibrium
dialysis probe, have been reported in abstract form (11),
but such a technique is not acceptable in the study of
normal human physiology. Indirect methods to quantitate
brain glucose concentrations, such as those based on
measuring the difference between glucose concentrations
in the arterial circulation and the venous effluent of the
brain (12), have provided important insights into under-
standing the regulation of brain-glucose uptake but are
limited by the model assumptions used for data analysis
(13). Positron emission tomography (PET) has also been
used to effectively measure regional rates of cerebral
glucose metabolism (14), but this method is limited by
frequent reliance on a non-native glucose analog, an
inability to directly measure metabolite concentration, and
difficulty separating signals derived from different chemi-
cal species. PET also has difficulty obtaining serial studies
from the same subject due to the radiation risks posed by
the isotope used in the study (14).
Our group has recently developed magnetic spectro-
scopic methods that allow us to directly and noninvasively
measure brain glucose concentrations in living humans
during periods of tightly controlled plasma glucose
(15,16). We used these methods to examine the hormonal
regulation of glucose concentration in both the gray and
white matter tissue of healthy humans. Our studies were
designed to test the hypothesis that cerebral glucose
transport/metabolism is largely an insulin-independent
process. We also sought to determine whether gray and
white matter glucose concentrations and metabolic rates
differ under steady-state conditions.
RESEARCH DESIGN AND METHODS
Healthy subjects were recruited from the students and staff at the University
of Minnesota. Before participation, subjects provided informed consent as
governed by the Institutional Review Board at the University of Minnesota.
Magnetic resonance spectroscopy (MRS) was used to measure brain glucose
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concentrations. During the spectroscopic studies, plasma concentrations of
both glucose and insulin were controlled at a constant target level using the
glucose/insulin clamp technique. We performed two sets of experiments to
address our study hypothesis.
Experiment 1. Subjects came to the Center for Magnetic Resonance Re-
search in the morning after an overnight fast. In preparation for the study, an
intravenous catheter was placed retrograde into one foot for the acquisition of
blood samples and two additional intravenous catheters were placed into the
upper extremities for the delivery of somatostatin, insulin, and glucose. The
leg used for blood sampling was wrapped in heated towels and hot packs to
arterialize the venous blood (17). After obtaining baseline samples for glucose
and ketones, a somatostatin infusion was begun and advanced to a rate of 0.16
g  kg–1  min–1 for 30 min to suppress endogenous insulin secretion (18).
Once the target somatostatin infusion rate had been achieved, glucose (50%
dextrose) was infused as necessary to achieve and maintain the plasma
concentration at 16.7 mmol/l. Beginning with the initiation of the somatostatin
infusion, blood samples were obtained every 5 min for determination of
plasma glucose concentration (using a Beckman Autoanalyzer). Additional
samples were obtained every 30 min for later determination of serum insulin
concentrations by radioimmunoassay (19). At the end of the first 60 min of
somatostatin infusion, subjects were placed into the 4 Tesla magnet for
examination by 1H-MRS in the absence of insulin (period I). When the
collection of the spectral data was complete, subjects were removed from the
magnet, given an intravenous infusion of insulin at a rate of 2.0 mU  kg–1 
min–1, and maintained at a plasma glucose concentration of 16.7 mmol/l. The
insulin infusion rate was selected to bring subjects to a serum insulin
concentration in the high physiological range. After 1 h, subjects were placed
back into the magnet and spectral data were collected in the presence of
insulin (period II). Figure 1 details the protocol followed for experiment 1.
Experiment 2. For these experiments, subjects also reported to the Center
for Magnetic Resonance Research in the morning after an overnight fast. The
protocol as detailed for experiment 1 was followed, except that at time 0,
insulin was begun at a rate of 0.5 mU  kg–1  min–1. The insulin infusion rate
was selected to bring subjects to a serum insulin concentration in the
physiological range. After 45 min, subjects were either maintained at eugly-
cemia or given a bolus injection of dextrose (50% in water) to bring them to
target glycemia (5–30 mmol/l). Plasma glucose was then clamped at target
glycemia by the infusion of dextrose (50% in water), and subjects were placed
in the magnet for data acquisition. After an additional 45 min, some subjects
were given an additional bolus injection of dextrose to bring them to a second
hyperglycemic target.
MRS. Experiments were performed on a 4 Tesla Siemens/Oxford magnet
interfaced to a Varian console as previously described (16,20). Subjects were
placed supine on a bed above the surface coil and their heads were held in
place by cushions. To minimize exposure to gradient noise, all subjects wore
earplugs. A quadrature transmit/receive RF coil consisting of two 14-cm
diameter single-turn coils was used (21). A 16–27 ml nominal volume of gray
matter–rich occipital cortex was selected for study for both experiments 1 and
2. For experiment 2, an additional 16 ml nominal volume of periventricular
white matter–rich tissue was also selected for study. Localization of the
signals was based on T1-weighted MDEFT (22) or FSE (23) imaging. Localized
shimming was performed using FASTMAP (24), which has shown consistent
7- to 8–Hz linewidths for the water resonance at 4 Tesla. For the measure-
ments, we used TE 4–20 ms, TM 33 ms, TR 4.5 (25). Water suppression
was accomplished by the application of four 25-ms Gaussian pulses (26) or by
applying a series of RF pulses according to the VAPOR scheme (27). In either
case, we verified that water suppression did not affect the signal by 5%
outside 0.4 ppm. Outer volume saturation was achieved in slices adjacent to
the volume of interest using hyperbolic secant pulses with variable RF power
(28). Free induction decays were averaged over a time period of 1 min,
stored separately in memory, and then corrected for small frequency changes
and averaged over at least 10 min. In each case, the plasma glucose
concentrations were maintained at steady state for at least 20 min before
spectral data were acquired. For experiment 1, data were collected over a
minimum of 10 min while glycemia was clamped at the target level. For
experiment 2, data were acquired in alternating mode simultaneously from the
occipital and the periventricular regions over a minimum of 20 min, during
which glycemia was clamped at target level.
Localized proton nuclear magnetic resonance (NMR) signals, obtained by
the methods described above, were zero filled and apodized with 2-Hz
exponential linebroadening. Peak areas were quantified using peak-fitting
software supplied by the spectrometer manufacturer as previously described
(15,16). Quantification of the glucose peak at 5.23 ppm was performed as
previously described and validated by comparison with measurements made
using 13C-MRS in our laboratory (16). In brief, the area under the glucose peak
at 5.23 ppm was calculated relative to the area under the creatine methyl
resonance at 3.04 ppm. For gray matter–rich regions, the concentration of
creatine was set to 10 mol/g wet wt, based on cortical concentrations of 9.6
mol/g wet wt (29) and on contributions of 1 mol/g wet wt -aminobutyric
acid and 1–2 mol/g wet wt glutathione in this region of the brain (30). The
creatine concentration in the white matter–rich voxels was calculated to that
in the gray matter using the relative requirements in RF power as a means to
correct for the small differences in RF coil sensitivity. The half-volume RF coil
design we used (21) resulted in the 90° RF power setting, varying by 1–2 dB,
which corresponds to a signal correction between 12 and 25%. The creatine
concentration was 7.3  0.9 mol/g wet wt (mean  SD) for the white
matter–rich areas, which suggests that the majority of our voxel contained
white matter according to Hetherington et al. (31); this conclusion was further
supported by the approximately twofold higher choline to creatine ratio.
Data analysis. Data are means  SE. To minimize the potential effects of
intersubject variation and modifications to magnetic resonance methodology,
all data acquired during experiment 1 were evaluated based on intrasubject
paired comparison, using observations obtained during the same study
session. The data acquired during experiment 2 were analyzed using the
reversible Michaelis-Menten model as previously described (16). This model
assumes that trans membrane glucose influences the affinity for cis mem-
brane glucose transport (product inhibition). Differences between groups
were detected using Student’s t test.
RESULTS
Experiment 1. Seven healthy subjects (four women and
three men) were recruited for participation in our investi-
gation. Their mean age was 30  2 years, and their mean
BMI was 21.8  0.2 kg/m2. During period I, when soma-
tostatin and glucose were infused, the serum insulin
concentration was 16  7 pmol/l and the plasma glucose
concentration was maintained at 16.5 0.5 mmol/l. During
period II, when somatostatin, glucose, and insulin were
infused, serum insulin rose to 668  81 pmol/l and plasma
glucose remained stable at 16.0  0.4 mmol/l.
The glucose signal at 5.23 ppm in the 1H spectrum was
easily resolved under the hyperglycemic conditions of our
study (Fig. 2). No difference was found between the brain
glucose concentrations measured in the absence and
presence of insulin. During period I, when insulin secre-
tion was suppressed, brain glucose concentration was
5.3  0.3 mol/g wet wt, whereas during period II, when
insulin was infused at 2.0 mU  kg–1  min–1, brain glucose
was 5.5  0.3 mol/g wet wt (P  NS) (Fig. 3). The 95%
FIG. 1. Protocol for experiment 1. Somatostatin infusion was begun at
time zero and advanced to a rate of 0.16 g  kg–1  min–1 for 30 min and
then maintained throughout the study. Glucose infusion was begun at
minute 30 to maintain a constant plasma glucose concentration of 16.7
mmol/l. 1H-MRS was performed from minute 60 to 90 (period I) for
later calculation of brain glucose concentration in the absence of
insulin. Insulin was begun at 2.0 mU  kg–1  min–1 at minute 90. 1H-MRS
was performed from minute 150 to 189 (period II) for later calculation
of brain glucose concentration in the presence of insulin.
INSULIN AND BRAIN GLUCOSE TRANSPORT
2204 DIABETES, VOL. 50, OCTOBER 2001
confidence interval for the difference in brain glucose
concentration measured during periods I and II was 0.1–
0.9 mol/g wet wt, and the standard deviation of this
difference was 0.2 mol/g wet wt. With this variability
around the mean, our sample size of seven provided an
80% likelihood of identifying a difference of 0.3 mol/g
wet wt between the brain glucose concentration measured
in the absence and presence of insulin and a 90% likeli-
hood of detecting a difference 0.4 mol/g wet wt.
Although the analysis was based on paired statistics and
was therefore considered to be independent of interindi-
vidual differences, we sought to further evaluate our
findings by generating in vivo difference spectra for each
subject. These difference spectra were created by sub-
tracting the 1H spectrum acquired in the absence of insulin
from that acquired in the presence of insulin. In every
subject, the resulting spectrum was a flat line, as shown in
Fig. 2, suggesting that any difference in brain glucose
signal acquired under the two experimental conditions
was below the noise level of the instrument.
Experiment 2. Twenty healthy subjects were recruited
for participation in this experiment. Their mean age was
35  2 years, and their mean BMI was 26.1 kg/m2. Brain
glucose concentrations were measured at serum glucose
concentrations ranging from 4.4 to 24.5 mmol/l. Serum
insulin concentrations averaged 108  6 pmol/l during
these experiments. Figure 4 shows representative spectra
acquired simultaneously from both gray and white matter–
rich regions in a single subject.
The relationship between plasma glucose concentration
and brain glucose concentration in both the gray and white
matter–rich areas was observed to be linear (Fig. 5).
FIG. 2. Effect of insulin infusion on cerebral metabolites as measured
by 1H-MRS. During a hyperglycemic clamp study, a subject was infused
with somatostatin (0.16 g  kg–1  min–1), and plasma glucose was held
constant at 15 mmol/l. After 60 min of stable glycemia, a 1H spectrum
was obtained from the occipital cortex (I. glucose infusion). The
subject was then removed from the magnet and given an infusion of
insulin (2 mU  kg–1  min–1) and a second 1H spectrum was obtained at
the end of 90 min (II. glucose  insulin infusion). An in vivo difference
spectrum was obtained by subtracting spectrum I from spectrum II.
The glucose peaks at 5.23 and 3.44 ppm are readily seen in the spectum
of standard glucose solution and in spectrums I and II, but were found
to be absent in the in vivo difference spectrum.
FIG. 3. Effect of insulin infusion on brain glucose concentrations.
Seven subjects were studied using the protocol described in the text.
Brain glucose concentrations measured without insulin were not dif-
ferent from concentrations measured with insulin. , Individual sub-
jects; f, means  SE.
FIG. 4. 1H-MRS of gray and white matter. A single subject was studied
at stable hyperglycemia during the infusion of somatostatin (0.16 g 
kg–1  min–1) and insulin (0.5 mU  kg–1  min–1). Spectra were acquired
simultaneously from a 27-ml volume of gray matter–rich cortex (A) and
a 16-ml volume of white matter–rich periventricular tissue (B). Cho,
choline; Cr, creatine; Glc, glucose; Glu, glutamate; Ins  inositol; NAA,
N-acetyl-aspartate.
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Reversible Michaelis-Menten kinetics fit these data best, as
we previously found in experiments in which serum
insulin concentrations were suppressed by the infusion of
somatostatin (16). The kinetics constants calculated for
the occipital cortex from these experiments with insulin
were indistinguishable from the constants calculated from
the data previously obtained during the experiments with-
out insulin (Table 1).
In 10 experiments, data were simultaneously acquired
from both the gray and white matter–rich regions during
stable glycemia. As shown in Table 2, the values calculated
for the white matter–rich periventricular tissue were sig-
nificantly lower than the values calculated for the gray
matter–rich occipital cortex (P  0.01). However, when
the data were corrected for the small difference in water
content between gray (0.83 ml/g) and white (0.75 ml/g)
matter (32), the average ratio between gray and white
matter glucose concentration was 1.04  0.04, which is no
longer significantly different from 1.0, as judged from
fitting y  ax. No statistically significant differences were
found between kinetic constants calculated for these
separate regions of cerebral tissue (Table 1).
DISCUSSION
The purpose of these experiments was to determine
whether insulin plays a significant role in the regulation of
cerebral glucose transport/metabolism in healthy human
subjects. To address this question, we used the novel
technique of high-field 1H-MRS and, for the first time,
directly and noninvasively examined the effect of this
hormone on the concentration of native glucose in the
living human brain. We found that the infusion of insulin
was without significant effect on the in vivo glucose
concentration measured in the gray matter–rich occipital
cortex of normal human volunteers. We further observed
that the glucose transport kinetics calculated from data
acquired from the occipital cortex in the presence of
insulin were not different from those calculated previously
in the absence of insulin. Taken together, these findings
support the hypothesis that cerebral glucose transport/
metabolism are largely an insulin-independent process.
The role of insulin in the regulation of brain-glucose
metabolism has long been an area of controversy. Al-
though most investigators have concluded that insulin was
without effect on glucose transport across the blood-brain
barrier (3–6,9), Hertz et al. (1) reported that insulin
increased glucose transport in humans and Namba et al.
(8) made similar observations in rats. However, a recent
re-evaluation by Knudsen et al. (33) of the data from Hertz
et al. (1) suggested that insulin may not truly have an effect
on glucose transport/metabolism in humans, a conclusion
that is also supported by the report of Cranston et al. (7).
Interestingly, both insulin receptors (34–36) and insulin-
sensitive GLUT4 (37–41) have been found at the blood-
brain barrier, and insulin has been shown to be an
important modulator of the autonomic response to hypo-
glycemia (42) and of feeding behavior (43). Insulin crosses
the blood-brain barrier via receptor-mediated transcytosis.
Despite the obvious importance of the hormone in regu-
lating some cerebral functions, our observations, particu-
larly the finding that the in vivo difference spectrum
created by subtracting the data collected in the presence
of insulin from that collected in its absence is a flat line,
provide support for the hypothesis that insulin does not
alter glucose content or any other brain metabolites
detectable by 1H-NMR spectroscopy. Hence, insulin ap-
FIG. 5. Relationships between glucose concentrations in plasma and
brain at physiologic insulin levels. Healthy subjects participated in
clamp experiments as described in RESEARCH DESIGN AND METHODS. Each f
represents a single experiment. A: Data acquired from the periven-
tricular white matter of 10 subjects during a total of 18 experiments. B:
Data acquired from the gray matter–rich occipital cortex of 23 subjects
during a total of 31 experiments. A linear relationship was found
between plasma glucose concentrations and the concentrations of
glucose measured in each brain region.
TABLE 1
Kinetic constants calculated using reversible Michaelis-Menten
model
Kt (mmol/l) Tmax/CMRglc
White matter–rich region
in the presence of insulin 1.96 2.45 2.15  0.25
Gray matter–rich cortex
in the presence of insulin 0.98 2.13 2.24 0.23
Gray matter–rich cortex
in the absence of insulin 0.6  2.0 2.3  0.2
Data are means  SE. Data previously published (16).
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pears to be without effect on glucose transport across the
blood-brain barrier when metabolism remains unchanged.
In our first experiment, we used a paired comparison to
determine whether insulin altered intracerebral glucose
concentrations. With a sample size of seven, this study had
sufficient power to detect a difference as small as 0.36
mol/g wet wt, with 90% likelihood. Such a value repre-
sents 7% of the mean brain glucose concentration mea-
sured during our experiments and is unlikely to be of
major physiological significance. Thus, although a small
effect of insulin on glucose transport across the blood-
brain barrier cannot be completely eliminated with our
data, such as an effect on the slow glycogen metabolism in
brain (44), we feel confident that this hormone does not
play a clinically relevant role in the regulation of brain-
glucose uptake.
Glucose concentrations in the brain are achieved
through a careful balance between glucose entering the
brain across the blood-brain barrier and glucose leaving
the brain through metabolism. For glucose concentration
to remain constant under steady-state conditions, the rate
of glucose influx must equal the rate of glucose efflux.
Recent investigations using PET have demonstrated that
insulin was without effect on the metabolic rate of glucose
in the cerebral cortex of humans (7,9). These observa-
tions, coupled with the data presented in the present
study, provide strong evidence that insulin is without
effect on the kinetics of glucose transport across the
blood-brain barrier. Future investigation into the role of
insulin in the regulation of intracerebral-glucose metabo-
lism will therefore be of interest. Particularly intriguing
are the observations of Nelson et al. (45), who reported
that insulin administration before death was shown to
increase the amount of glycogen present in the post-
mortem rat brain. However, the micromolar glycogen
concentrations that have recently been measured in anes-
thetized rats in vivo (44) suggest that the contribution of
glycogen to overall cerebral glucose metabolism must be
small.
In the second experiment, we measured the kinetic
constants for glucose transport across the blood-brain
barrier for both gray and white matter–rich regions. Using
the reversible Michaelis-Menten model, the resulting ki-
netic constants were not statistically significantly differ-
ent, implying that insulin has similar effects on glucose
uptake/metabolism in both gray and white matter glucose
uptake/metabolism. Interestingly, we observed that the
steady-state concentrations of the white matter–rich
periventricular tissue were significantly lower than simul-
taneously measured concentrations in the gray matter–
rich occipital cortex. This quantification (mol/g wet wt)
was performed on a per gram of wet weight basis, and the
ratio between gray and white matter was 1.4  0.2.
However, the results do not imply that a significant
chemical glucose concentration gradient exists between
white and gray matter. When expressing the glucose
concentrations on a per milliliter of brain water basis, i.e.,
when correcting for the small difference in water content
between gray (0.83 ml/g) and white (0.75 ml/g) matter (32),
the average ratio between gray and white matter glucose
concentration (mol/ml brain water) was 1.1  0.0.1,
which is no longer significantly different from 1.0. There-
fore, we conclude that the chemical concentration gradi-
ent between gray and white matter is not significant.
Because glucose transport in the brain occurs by facili-
tated diffusion, this implies that there is no net glucose
mass transfer between gray and white matter. Other
investigators have consistently measured the metabolic
rate of glucose in white matter to be significantly lower
than that in gray matter (9,10), which implies that there are
TABLE 2
Simultaneously measured gray and white matter glucose concentrations during stable glycemia
Subject
Plasma glucose
(mmol/l)
Gray matter
glucose
(mol/g
wet wt)
White matter
glucose
(mol/g
wet wt)
Gray matter
glucose:
white matter
glucose
(mol/g wet
wt)
Gray matter
glucose
(mol/ml
brain water)*
White matter
glucose
(mol/ml
brain water)†
Gray matter
glucose:
white matter
glucose
(mol/ml
brain water)
1 8.4 0.1 2.4 2.4 1.0 2.9 3.2 0.9
2 5.9 0.1 2.1 1.0 2.1 2.5 1.3 1.9
3 13.8 0.1 4.0 3.8 1.1 4.8 5.1 0.9
4 7.8 0.1 2.3 1.9 1.2 2.8 2.5 1.1
5 20.5 0.3 5.5 4.8 1.1 6.6 6.4 1.0
6 8.1 0.1 2.4 1.3 1.8 2.9 1.7 1.7
7 23.2 0.3 6.9 6.7 1.0 8.3 8.9 0.9
8 13.8 0.1 5.2 4.3 1.2 6.3 5.7 1.1
9 19.1 0.1 7.2 5 1.4 8.7 6.7 1.3
10 8.0 0.1 2.3 2.2 1.0 2.8 2.9 1.0
11 24.2 0.5 6.6 6.4 1.0 8.0 8.5 0.9
12 16.3 0.2 4.6 3.9 1.2 5.5 5.2 1.1
13 7.7 0.1 1.9 1 1.9 2.3 1.3 1.8
14 17.9 0.4 4.0 3.7 1.1 4.8 4.9 1.0
15 10.6 0.1 3.2 2.6 1.2 3.9 3.5 1.1
16 16.3 0.1 4.6 3.6 1.3 5.5 4.8 1.1
17 4.7 0.1 0.7 0.8 0.9 0.8 1.1 0.7
Mean  SE — — — 1.4 0.2 — — 1.1 0.1
Data are means  SE. *Assumed gray matter water content  0.83 ml/g (31); †assumed white matter content  0.75 ml/g (31).
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marked differences in Tmax between these tissues. This
difference can be considered to also reflect the density of
the transporter at the blood-brain barrier (the permeability
surface area product); therefore, it is related to the blood
volume in gray and white matter. Thus, it appears that
brain glucose content is heavily regulated in normal brain
tissue, underscoring the imporant role it plays in normal
brain function.
The study of in vivo cerebral glucose metabolism in
humans has been limited by the inability to directly and
noninvasively measure brain glucose concentrations.
Techniques such as the indicator dilution method (12) and
PET have provided important insights into the regulation
of cerebral glucose transport and metabolism in humans
but are by their very nature indirect and based on assump-
tions that are difficult to experimentally confirm. The
microdialysis method allows direct measurement of extra-
cellular brain glucose, which appears to be equal to
intracellular glucose concentrations (46), but may become
inaccurate over time because of the scarring that occurs in
the tissue surrounding the probe. In addition, the invasive-
ness of the technique precludes its application to general
investigation of healthy volunteers. 13C-MRS at low field
has offered a solution to the limitations presented by these
indirect or invasive techniques, but it requires the infusion
of 13C-glucose to achieve sufficient signal-to-noise to allow
quantification of brain glucose content (47). 1H-MRS does
not require the infusion of substrate and uniquely allows
for the direct study of native glucose in brain tissue.
However, at lower field strengths, the resolution of the
glucose signal in the 1H spectrum has been difficult. Most
investigators working at lower field strengths have relied
on a glucose signal of 3.43 ppm for quantification purposes
(48–50). However, this peak overlaps with myo-inositol
and does not easily allow for precise quantification (15,51).
The peak at 5.23 ppm is free of spectral overlap with other
metabolic species (15) and can be well resolved for
quantification using a field strength of 4 Tesla and the
methods of shimming used in the current study.
One limitation of 1H-MRS is the difficulty that can be
encountered in measuring brain glucose content under
hypoglycemic conditions. However, if long acquisition
times are used so that the signal-to-noise ratio can be
optimized, data sufficient for accurate quantification of
glucose can be acquired. Another limitation is that the
glucose content measured in a region reflects the glucose
present in both cerebral tissue and the intravascular
space. However, since cerebral blood volume is minimal
(on the order of 2–4% of total volume) (52–54), the
contribution of blood glucose to the measurement of brain
glucose is small and without effect on the calculation of
glucose transport kinetics across the blood-brain barrier.
At a plasma concentration of 15 mmol/l, the contribution
of blood to the glucose concentration measured in gray
matter would be 0.6 mmol/l or 10% of the total glucose
concentration measured in a volume of cerebral tissue.
When the data are adjusted for the contribution of intra-
vascular glucose to the overall glucose concentration in
the brain, the conclusions drawn from the data are un-
changed. Consequently, 1H-MRS at high field strengths
represents the best way to directly measure the concen-
trations of native glucose in the brain of human volun-
teers. This is supported by the observation of resolved
glucose resonances in the rat brain at 9.4 Tesla (27).
In summary, our experiments demonstrate that 1H-MRS
at 4 Tesla is a powerful investigative tool with which to
directly and noninvasively measure the concentration of
glucose in cerebral tissue. Using this technique, we dem-
onstrated that the infusion of insulin during constant
hyperglycemia was without effect on brain glucose con-
centrations and that the kinetics of glucose transport
calculated from data acquired in the presence of insulin
are not different from those calculated from data acquired
in the absence of insulin. In addition, we found that the
kinetic constants calculated for both gray and white
matter–rich regions in the presence of insulin are similar,
indicating that the hormone has similar effects on glucose
uptake/metabolism in both types of cerebral tissue. All
together, this study demonstrated the power that MRS
brings to the study of in vivo metabolism and illustrated
how the method can be used to uniquely and directly
address questions important in human physiology and
disease.
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